What is HC Wainwright’s Forecast for SGMT FY2030 Earnings?

Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) – HC Wainwright cut their FY2030 earnings per share (EPS) estimates for shares of Sagimet Biosciences in a report issued on Friday, November 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $2.09 per share for the year, down from their previous estimate of $2.28. HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.14) per share.

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.05).

Several other research analysts also recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sagimet Biosciences in a research note on Thursday, October 15th. Citizens Jmp decreased their price objective on Sagimet Biosciences from $29.00 to $27.00 and set a “market outperform” rating on the stock in a report on Thursday, October 1st. Wall Street Zen cut shares of Sagimet Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Wells Fargo & Company set a $27.00 target price on shares of Sagimet Biosciences in a report on Friday. Finally, Oppenheimer upped their target price on shares of Sagimet Biosciences from $33.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, October 1st. Nine analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Sagimet Biosciences has a consensus rating of “Moderate Buy” and an average price target of $26.07.

Get Our Latest Stock Report on Sagimet Biosciences

Sagimet Biosciences Price Performance

NASDAQ SGMT opened at $10.13 on Monday. The stock’s 50 day simple moving average is $9.86 and its 200-day simple moving average is $7.71. The company has a market cap of $629.68 million, a PE ratio of -8.51 and a beta of 3.43. Sagimet Biosciences has a 1-year low of $4.50 and a 1-year high of $11.45.

Institutional Investors Weigh In On Sagimet Biosciences

A number of large investors have recently made changes to their positions in SGMT. Marshall Wace LLP acquired a new stake in shares of Sagimet Biosciences in the third quarter valued at approximately $7,433,000. Nantahala Capital Management LLC acquired a new position in Sagimet Biosciences during the third quarter worth $4,662,000. Renaissance Technologies LLC boosted its stake in Sagimet Biosciences by 82.6% during the first quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock worth $3,268,000 after buying an additional 282,969 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in Sagimet Biosciences during the second quarter worth $3,119,000. Finally, AWM Investment Company Inc. boosted its stake in Sagimet Biosciences by 275.0% during the third quarter. AWM Investment Company Inc. now owns 300,000 shares of the company’s stock worth $2,964,000 after buying an additional 220,000 shares during the last quarter. 87.86% of the stock is currently owned by hedge funds and other institutional investors.

About Sagimet Biosciences

(Get Free Report)

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body’s production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.

Recommended Stories

Earnings History and Estimates for Sagimet Biosciences (NASDAQ:SGMT)

Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.